vilastobart
Generic: XTX101·Code: XTX101
vilastobart: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Xilio Therapeutics, Inc. (XLO) | Phase 1/Phase 2 |
Clinical Trials (1)
A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of Vilastobart (XTX101) Monotherapy and Vilastobart (XTX101) and Atezolizumab Combination Therapy in Patients With Advanced Solid Tumors
Frequently asked questions
Who is developing vilastobart?
vilastobart is being developed by Xilio Therapeutics, Inc..
How many clinical trials involve vilastobart?
BioSniper tracks 1 clinical trial involving vilastobart.
Get deeper analysis on vilastobart
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis